Summary
Sleep disturbance has become a subject of serious study only over the past few years, but even so there is already an increasing awareness of the nature of insomnia and a greater understanding of the role which hypnotics should play in clinical medicine.
An hypnotic may be used to shorten sleep onset when there is difficulty in jailing asleep, to reduce nocturnal wakefulness, or to provide an anxiolytic effect during the next day when insomnia is accompanied by a marked element of anxiety. The purpose of an hypnotic is to meet one or more of these clinical problems; to ensure that the patient is given the most useful medication, consideration must be given to duration of activity. This depends on the absorption, distribution and elimination characteristics of the drug.
It is now appreciated that the most appropriate use of hypnotics is in the individual with insomnia of recent origin. An hypnotic with the most relevant pharmacokinetic profile should be used for the shortest period of time and then only as required, while low doses will ensure freedom from adverse effects.
The place of hypnotics in chronic insomnia remains less certain. Their careful use may well be of benefit, though it must be part of a well defined clinical strategy. Assessment of the patient is essential to identify any specific conditions which would impair sleep.
Similar content being viewed by others
References
Amrein R, Borey F, Cano JP, Eckert M, Ziegler WH, et al. Pharmacokinetics and pharmacodynamics of flurazepam in man. Investigation of the relative efficacy of flurazepam, desalkyl-flurazepam and placebo under steady state conditions. Drugs Under Experimental and Clinical Research 9: 85–89, 1983
Bechtel WD. Pharmacokinetics and metabolism of brotizolam in humans. British Journal of Clinical Pharmacology 16: 279S–283S, 1983
Bixler EO, Kales JD, Kales A, Jacoby JA, Soldatos CR. Rebound insomnia and elimination half life: assessment of individual subject response. Journal of Clinical Pharmacology 25: 115–124, 1985
Boxenbaum HG, Posmanter HN, Macasieb T, Geitner KA, Weinfeld RE, et al. Pharmacokinetics of flunitrazepam following single- and multiple-dose oral administration to healthy human subjects. Journal of Pharmacokinetics and Biopharmaceutics 6: 283–293, 1978
Breimer DD, Bracht H, de Boer AG. Plasma level profile of nitrazepam (Mogadon) following oral administration. British Journal of Clinical Pharmacology 4: 709–711, 1977
Consensus Conference. Drugs and insomnia. The use of medications to promote sleep. Journal of the American Medical Association 251: 2410–2414, 1984
Dement WC. Rational basis for the use of sleeping pills. Pharmacology 72(Suppl. 2): 3–38, 1983
Divoll M, Greenblatt DJ, Harmatz JS, Shader RI. Effect of age and gender on disposition of temazepam. Journal of Pharmaceutical Sciences 70: 1104–1107, 1981
Eckert M, Ziegler WH, Cano JP, Borey F, Amrein R, et al. Pharmacokinetics and pharmacodynamics of flurazepam in man. Pharmacokinetics of desalkylflurazepam and hydroxyethylflurazepam after a single intravenous injection in comparison with orally administered flurazepam. Drugs Under Experimental and Clinical Research 9: 77–84, 1983
Fuccella LM. Bioavailability of temazepam in soft gelatine capsules. British Journal of Clinical Pharmacology 8: 31S–35S, 1979
Gaillot J, Heusse D, Houghton GW, Marc Aurele J, Dreyfus JF. Pharmacokinetics and metabolism of zopiclone. Pharmacology 27(Suppl. 2): 76–91, 1983
Greenblatt DJ, Divoll M, Harmatz JS, Shader RI. Oxazepam kinetics: effects of age and sex. Journal of Pharmacology and Experimental Therapeutics 215: 86–91, 1980
Hauri P. The sleep disorders, The Upjohn Company, Kalamazoo, Michigan, 1982
Heizmann P, Eckert M, Ziegler WH. Pharmacokinetics and bioavailability of midazolam in man. British Journal of Clinical Pharmacology 16: 43S–49S, 1983
Houghton GW, Dennis MJ, Templeton R, Martin BK. A repeated dose pharmacokinetic study of a new hypnotic agent, zopiclone (Imovane). International Journal of Clinical Pharmacology, Therapy and Toxicology 23: 97–100, 1985
Jochemsen R, Wesselman JGJ, Hermans J, van Boxtel CJ, Bremer DD. Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration. British Journal of Clinical Pharmacology 16: 285S–290S, 1983a
Jochemsen R, Wesselman JGJ, van Boxtel CJ, Hermans J, Breimer DD. Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects. British Journal of Clinical Pharmacology 16: 291S–297S, 1983b
Kales A, Kales JD. Evaluation and treatment of insomnia, Oxford University Press, 1984
Kaplan SA, Jack ML, Alexander K, Weinfeld RE. Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations. Journal of Pharmaceutical Sciences 62: 1789–1796, 1973
Klotz U, Zgegler G. Physiologic and temporal variation in hepatic elimination of midazolam. Clinical Pharmacology and Therapeutics 32: 107–112, 1982
Ladewig D. Abuse of benzodiazepines in Western European society — incidence and prevalence motives, drug acquisition. Pharmacopsychiatry 16: 103–106, 1983
McInnes GT, Bunting EA, Ings RMJ, Robinson J, Ankier SI. Pharmacokinetics and pharmacodynamics following single and repeated nightly administrations of loprazolam, a new benzodiazepine hypnotic. British Journal of Clinical Pharmacology 19: 649–656, 1985
Marks J, Nicholson AN. Drugs and insomnia. British Medical Journal 288: 261, 1984
Meilinger GD, Baiter MB, Uhlenhuth EH. Insomnia and its treatment. Archives of General Psychiatry 42: 225–232, 1985
Nicholson AN, Marks J. Insomnia: a guide for the medical practitioner. MTP Press Limited, Lancaster, 1983
Nicholson AN, Stone BM. Imidazobenzo-diazepines: sleep and performance studies in humans. Journal of Clinical Psycho-pharmacology 3: 72–75, 1983
Ochs HR, Greenblatt DJ, Verburg-Ochs B, Locniskar A. Comparative single dose kinetics of oxazolam, prazepam, and chlorazepate: three precursors of desmethyldiazepam. Journal of Clinical Pharmacology 24: 446–451, 1984
Pierce DM, Franklin RA, Harry TVA, Nicholson AN. Pharmacodynamic correlates of modified absorption: studies with lormetazepam. British Journal of Clinical Pharmacology 18: 31–35, 1984
Ziegler WH, Schaleh E, Leishman B, Eckert M. Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites. British Journal of Clinical Pharmacology 16: 63S–69S, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nicholson, A.N. Hypnotics. Drugs 31, 164–176 (1986). https://doi.org/10.2165/00003495-198631020-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198631020-00005